Order Article Reprints

Ridder DA, Urbansky LL, Witzel HR, Schindeldecker M, Weinmann A, Berndt K, Gerber TS, Köhler BC, Nichetti F, Ludt A, et al. Transforming Growth Factor-β Activated Kinase 1 (Tak1) Is Activated in Hepatocellular Carcinoma, Mediates Tumor Progression, and Predicts Unfavorable Outcome. Cancers. 2022; 14(2):430. https://doi.org/10.3390/cancers14020430

Ridder, Dirk Andreas, Lana Louisa Urbansky, Hagen Roland Witzel, Mario Schindeldecker, Arndt Weinmann, Kristina Berndt, Tiemo Sven Gerber, Bruno Christian Köhler, Federico Nichetti, Annekathrin Ludt, and et al. 2022. "Transforming Growth Factor-β Activated Kinase 1 (Tak1) Is Activated in Hepatocellular Carcinoma, Mediates Tumor Progression, and Predicts Unfavorable Outcome" Cancers 14, no. 2: 430. https://doi.org/10.3390/cancers14020430

Ridder, D. A., Urbansky, L. L., Witzel, H. R., Schindeldecker, M., Weinmann, A., Berndt, K., Gerber, T. S., Köhler, B. C., Nichetti, F., Ludt, A., Gehrke, N., Schattenberg, J. M., Heinrich, S., Roth, W., & Straub, B. K. (2022). Transforming Growth Factor-β Activated Kinase 1 (Tak1) Is Activated in Hepatocellular Carcinoma, Mediates Tumor Progression, and Predicts Unfavorable Outcome. Cancers, 14(2), 430. https://doi.org/10.3390/cancers14020430